Researchers at Vanderbilt University Medical Center used spatial transcriptomics to characterize acute rejection and response to immunomodulatory therapies following heart transplantation. The study linked cell-specific gene expression patterns to the development of cardiac allograft vasculopathy, a form of chronic rejection that limit...
A new study from Virginia Tech found that task switching in transplant surgeries increases one-year mortality rates by 14.8 percent, highlighting the need for efficient scheduling and workflow changes to minimize risks. The research also suggests that recovery time and surgeon experience level can mitigate these effects.
Researchers at Medical University of South Carolina engineered a new type of immune cell that can precisely target and neutralize antibody-producing cells complicit in organ rejection. This strategy could level the playing field for patients with limited eligibility for organs due to high rejection rates.
A new study by Mass General Brigham researchers has identified a natural 'brake' within the innate immune system that can prevent organ transplant rejection. The discovery highlights a promising target for new therapies and offers hope for longer-lasting transplant success and reduced need for lifelong immunosuppression.
A new device developed by Northwestern University researchers can detect temperature irregularities associated with inflammation and other body responses that arise with transplant rejection. This allows for earlier intervention, improving patient outcomes and increasing the odds of preserving donated organs.
Researchers have developed a highly sensitive immuno-CRISPR assay to detect acute kidney rejection in urine, potentially allowing for early diagnosis without invasive biopsy. The test uses CRISPR/Cas12a gene editing technology to identify biomarkers of rejection, such as CXCL9, with improved sensitivity compared to existing methods.
A new study reveals that urinary markers miR-155-5p and CXCL10 can predict acute rejection and organ dysfunction in kidney transplant patients. The findings suggest a potential for improved patient outcomes through biomarker-based monitoring after transplantation.
A new study published in PLOS Medicine has developed a 17-gene set to analyze peripheral blood samples and determine which patients are at risk of acute rejection after kidney transplantation. The test, called kSORT, was found to be highly accurate and clinically applicable, with an area under the curve of 0.93.
A study published in the New England Journal of Medicine shows that anti-thymocyte globulin reduces acute rejection incidence by 15.6% compared to basiliximab in high-risk kidney transplant patients. The treatment is expected to save millions of dollars in healthcare costs by preventing immune attacks and organ loss.
Lung transplant recipients with specific TLR4 gene variants experienced reduced acute rejection rates, suggesting a novel approach to preventing transplant rejection. Researchers believe this finding could lead to improved patient outcomes and survival rates.
Certican has been shown to target underlying causes of chronic allograft dysfunction and late graft loss, including acute rejection and vascular remodelling. The drug demonstrated superiority over azathioprine in reducing acute rejection episodes and pulmonary function decline.
A new study by UF researchers has shown that mycophenolate mofetil significantly decreases the risk of late acute rejection and increases kidney survival after transplantation. The drug also appears to prevent the severe scarring of the kidney, a common cause of organ malfunction or failure.
A new study found that patients receiving the drug Thymoglobulin had two and half times fewer episodes of acute kidney rejection than those receiving Simulect. The study's findings are significant as they show a potential benefit for up to half of kidney transplants from cadavers.